Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,314 Mln
P/E Ratio
--
P/B Ratio
14.72
Industry P/E
--
Debt to Equity
0.01
ROE
-0.87 %
ROCE
-86.62 %
Div. Yield
0 %
Book Value
5.58
EPS
-4
CFO
$-166.00 Mln
EBITDA
$-209.73 Mln
Net Profit
$-211.01 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Soleno Therapeutics (SLNO)
| 62.98 | 46.11 | 52.43 | 86.22 | 186.91 | 10.61 | -17.72 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Soleno Therapeutics (SLNO)
| 11.58 | 1,932.83 | -67.80 | -78.76 | -34.35 | 71.93 | -4.97 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release... tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Address: 100 Marine Parkway, Redwood City, CA, United States, 94065 Read more
President, CEO, COO & Director
Dr. Anish Bhatnagar M.D.
President, CEO, COO & Director
Dr. Anish Bhatnagar M.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Soleno Therapeutics Inc (SLNO) stood at $ 331 Mln as on 31-Dec-24
The share price of Soleno Therapeutics Inc (SLNO) is $73.26 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Soleno Therapeutics Inc (SLNO) has given a return of 186.91% in the last 3 years.
Soleno Therapeutics Inc (SLNO) has a market capitalisation of $ 3,314 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Soleno Therapeutics Inc (SLNO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Soleno Therapeutics Inc (SLNO) and enter the required number of quantities and click on buy to purchase the shares of Soleno Therapeutics Inc (SLNO).
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Address: 100 Marine Parkway, Redwood City, CA, United States, 94065
The CEO & director of Dr. Anish Bhatnagar M.D.. is Soleno Therapeutics Inc (SLNO), and CFO & Sr. VP is Dr. Anish Bhatnagar M.D..
There is no promoter pledging in Soleno Therapeutics Inc (SLNO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Soleno Therapeutics Inc. (SLNO) | Ratios |
|---|---|
|
Return on equity(%)
|
-87.35
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Soleno Therapeutics Inc (SLNO) was $0 Mln.
$-0.97
(
